New hope for rare pancreatic cancer: experimental drug enters trial
NCT ID NCT07121478
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called lurbinectedin in people with high-grade pancreatic neuroendocrine tumors (a rare, fast-growing cancer) who have already tried standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing. About 46 adults will take part in this Phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea